For the past month, GalsBio has been carrying out a crowdfunding campaign for the second round of funding for the Tulipon – a smart next-generation tampon.
The campaign is being carried out on the Israeli-based Pipelbiz platform. Further information can be seen at https://pipelbiz.com/Campaign/52898 which will be open till January 27th, 2022.
Tulipon is a product combining the benefits of tampons (with an applicator) and those of the reusable menstrual cup. This unique vaginal platform handles bleeding in a superior manner, and it provides the option of identifying and monitoring biomarkers from the vaginal secretions, essentially a monthly biopsy. For the first time, Tulipon will provide heavy menstrual bleeders (HMB) a holistic 12 hours worry-free (twice as long as a regular tampon), leak-free and ecological solution for handling their monthly bleeding.
Tulipon is a groundbreaking development in the female hygiene field that addresses two considerable needs: handling HMB and the monitoring and screening of a woman’s health. It provides these medical diagnostics by analyzing the collected natural secretions and monitoring them over time. Thus, early detection of various health conditions will be done by Tulipon and a dedicated smartphone app. The first health conditions that will be detected by Tulipon will be iron deficiency and uterine fibroids, with conditions like endometriosis and genital cancers to be addressed in the future.
The world of female hygiene has seen very little innovation in the last one hundred years, since the invention of the tampon. This is puzzling considering it is a 40 billion USD global market per year, and it is expected to be worth 51 billion USD/year by the year 2027.
About 20% of menstruating women experience Heavy Menstrual Bleeding (HMB) (more than 80ml of fluid) every month. As a result, they are forced to give up their daily routine, avoiding socializing and other activities. This is due to the lack of appropriate hygiene devices that can truly support and handle their monthly bleeding.
Tulipon will be eventually able to identify the possible causes of Heavy Menstrual Bleeding (HMB) ( 80ml or more of liquid). HMB has a variety of causes:
- Anemia: about 70% of menstruating women suffer from a lack of Iron due to HMB which can lead to detrimental results if left untreated.
- Perimenopause: 20% of women experience HMB at the onset of menopause. Many of the menopause symptoms can be avoided by taking appropriate treatment on time.
- Uterine fibroids: 70% of menstruating women will have fibroid prior to the age of 50. One indication of fibroids is HMB.
- Polycystic Ovarian Syndrome: common in 10% of women, 50% of them are not aware of their condition.
- Infection: Sexual Transmitted Diseases (STD) can result in HMB.
The startup, GalsBio, has raised $2 million so far, not including the current fundraising on the crowdfunding platform PipelBiz (https://pipelbiz.com/Campaign/52898). The entire amount came from AH trust of British billionaire Alan Howard, which earlier this year Bloomberg named the “secret hedge fund” that Howard personally manages.
Hilla Shaviv, CEO, GalsBio, said “in cardiology, everywhere you place your finger you encounter an existing patent. However, when I started researching menstrual blood flow, I found a vacuum: no patents, no innovation, empty space. It is also difficult to find researchers who are researching this subject – all the research done is on the cellular level. I deal with systems, mechanics, contractions, flow. Hardly anyone researches this nowadays. When I founded my first company, GalMedics, I used to say that it did not make sense that in 2007 no one could explain why half of the women had primary dysmenorrhea (menstrual cramps).”
GalsBio was founded by Hilla Shaviv in 2015 and is based in Mevasseret Zion, on the outskirts of Jerusalem. GalsBio is developing Tulipon, a disposable vaginal platform (internal wearable) device, with built-in diagnostics, with many applications for wellness, health screening, and monitoring. To date, GalsBio has 3 registered patents in the United States and EU, more patents pending approval in the United States and Europe, and more patents in the pipeline.
The GalsBio Team
Hilla Shaviv, founder and CEO of GalsBio, is a biomedical engineer, serial inventor, and entrepreneur in the women’s health arena, with more than 20 years of experience in medical device R&D.
Omer Shezifi, CTO at GalsBio has more than 25 years of extensive experience in R&D and product development with various technology and MedTech companies.
Rachel Braun Scherl, in charge of Marketing & Management at GalsBio, is a business builder, marketing, thought leader, board member, speaker, and best-selling author with a focus on women’s sexual and reproductive health. Among her clientele are Bayer, Merck, Pfizer, Allergan, J&J, and many start-up companies. Rachel is the inventor and founder of Semprae Laboratories, developing products for women’s sexual health. The company was sold to Innovus Pharmaceuticals in 2013.
Dr. Amos Ber, GalsBio’s in-house OBGYN, is a women & health expert and surgeon, OBGYN specialist with 30 years of experience in amniocentesis, pregnancy termination, contraception, and menopause. Dr. Ber is a household name in Israel as the co-author (along with Mrs. Tali Rozin) of their best-selling book “The Israeli Guide for Pregnancy and Childbirth”. Dr. Ber is a leading authority in Israeli gynecology, a senior doctor at Maccabi Healthcare Services, a member of the Israeli Menopause Association, and a former member of the European Society of Contraception and Reproductive Health.
Further information on the Crowdfunding campaign for GalsBio can be seen at https://pipelbiz.com/Campaign/52898
For further information – Hilla Shaviv, CEO, GalsBio Ltd.
hilla AT galsbio.com
Source: The Marker January 2022
About JLM- BioCity
News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/
JLM-BioCity is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.
We invite you, researcher, professional, investor, and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.
If you want your company featured in our blogs, news releases, please contact: info at jlm-biocity.org